Retatrutide

Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed for potent weight loss and metabolic enhancement. It significantly improves body composition, glycemic control, and metabolic rate through synergistic mechanisms affecting appetite regulation, insulin sensitivity, and energy expenditure. Retatrutide is currently under clinical evaluation for obesity and type 2 diabetes management, demonstrating superior efficacy compared to GLP-1 monotherapies like Semaglutide or Tirzepatide. It is currently undergoing Phase II/III clinical trials for

• GLP-1 receptor agonism (enhances insulin secretion, delays gastric emptying, reduces appetite)
• GIP receptor agonism (increases insulin sensitivity, suppresses appetite)
• Glucagon receptor agonism (enhances energy expenditure and fat oxidation)

• unit: mg

  low dose: 2

  frequency: Once weekly

  high dose: 12

  standard dose: 4

  administration route: Subcutaneous (SQ)

• Retatrutide is dosed weekly, typically starting at 2 mg for the first 4 weeks, then increasing by 2 mg increments every 4 weeks up to 12 mg. Overlapping with other incretin-based therapies (like GLP-1 or GIP agonists) should be avoided unless supervised.

common: ["GI effects (nausea, diarrhea, vomiting) — mild-moderate, diminish over time","Lower starting dose (2 mg vs 4 mg) reduces initial GI events"]

sequence: YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³

half life: Estimated >6 days

degradation: Primarily metabolized by proteolytic enzymes and renal clearance.

molecular weight: 4731.33

molecular formula: C223H343F3N46O70

tissue specificity: Acts on pancreatic beta cells, central nervous system (appetite centers), liver, and adipose tissue.

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.clinicalPMID 37366315 ↗
• Retatrutide-A Game Changer in Obesity Pharmacotherapy.reviewPMID 40563436 ↗